Matinas BioPharma to Webcast Conference Call Discussing Third Quarter 2022 Operational and Financial Results on November 2, 2022
27 oct. 2022 07h00 HE
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of...
Matinas BioPharma Announces Positive Interim Data from the Phase 2 EnACT Trial of MAT2203 for the Treatment of Cryptococcal Meningitis, Exceeding Primary Endpoint Threshold; Patient Survival in All-Oral Cohort 4 Regimen Currently 90%
21 oct. 2022 07h48 HE
|
Matinas BioPharma Holdings, Inc.
Two-week survival in Cohort 4 (all-oral regimen) was 95% in 40 patients receiving MAT2203 Mean Early Fungicidal Activity (EFA) of the rate of yeast clearance in cerebrospinal fluid exceeded the...
Matinas BioPharma to Present at the ThinkEquity Annual Global Investment Conference
21 oct. 2022 07h00 HE
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Oct. 21, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids...
Matinas BioPharma Announces Infectious Diseases Society of America (IDSA) has Selected the EnACT Phase 2 Trial Abstract of MAT2203 as its Outstanding Abstract and IDSA Awardee For IDWeek 2022
19 oct. 2022 07h10 HE
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of...
Matinas BioPharma to Present New MAT2203 (Oral Amphotericin B) Data During IDWeek 2022
12 oct. 2022 07h00 HE
|
Matinas BioPharma Holdings, Inc.
Interim data from all-oral Cohort 4 of the EnACT Trial of MAT2203 in Cryptococcal Meningitis to be revealed along with an overview of the entire Phase 2 trial Late-breaking data demonstrate that...
Matinas BioPharma Announces Chairman Succession Plan
21 sept. 2022 07h00 HE
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of...
Matinas BioPharma to Present at the H.C. Wainwright 24th Annual Global Investment Conference
07 sept. 2022 07h00 HE
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids...
Matinas BioPharma Reports Second Quarter 2022 Financial Results and Highlights Recent Progress
11 août 2022 06h30 HE
|
Matinas BioPharma Holdings, Inc.
75% of Patients Enrolled to Date in Cohort 4 of EnACT (MAT2203 in Cryptococcal Meningitis); Topline Data in Late Q3/Early Q4 2022 FDA Provides Flexibility and Clarity on Phase 3 Program and Single...
Matinas BioPharma to Participate in the BTIG Biotechnology Conference
01 août 2022 07h00 HE
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids...
Matinas BioPharma to Webcast Conference Call Discussing Second Quarter 2022 Financial and Operational Results on August 11, 2022
28 juil. 2022 16h15 HE
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., July 28, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of...